SEC Form 4 · accession 0001209191-18-001305
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W Sherman
Officer — EVP and Chief Medical Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 3, 2018 · 6:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jan 2, 2018 | M | 15,500 | — | A | 209,299 | D | |
| Ordinary SharesF3 | Jan 2, 2018 | F | 7,680 | $15.02 | D | 201,619 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4 | — | Jan 2, 2018 | M | 15,500 | D | — | — | Ordinary Shares | 15,500 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Includes 1,449 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program.
- F3Reflects the net settlement of ordinary shares of the Issuer in connection with the vesting of restricted stock units.
- F4On January 2, 2014, the reporting person was granted 62,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.